secwatch.observer — SEC 8-K summary
======================================

Issuer:     Voyager Therapeutics, Inc. (VYGR)
CIK:        0001640266
Form:       8-K
Filed at:   2026-01-08T23:59:59+00:00
Accession:  0001104659-26-001955
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Voyager Therapeutics outlines pivotal 2026 milestones: tau programs, capsid validation, NeuroShuttle data
--------------------------------------------------------------------------------

- Biogen's BIIB080 Phase II data expected mid-2026; Voyager's VY1706 gene therapy first-in-human in H2 2026.
- VY7523 anti-tau antibody trial fully enrolled; tau PET imaging data expected H2 2026.
- Neurocrine plans to initiate clinical trial with NBIB-‘223 for Friedreich's ataxia in 2026.
- ALPL-NeuroShuttle shows similar target engagement to TfR shuttle with more sustained brain exposure; partnering interest strong.
- Four wholly owned and partnered IV-delivered neuro gene therapy programs advanced to preclinical toxicology.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1640266/000110465926001955/0001104659-26-001955-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1640266/000110465926001955/tm262517d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-001955

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer